$CLLS free signal of the week.With a positive fundamental behind, we may see some action today on NASDAQ:CLLS
CCCellectis S.A.
2.86USDR
+0.07+2.51%
Last update at 20:54 GMT
2.86USD
0.000.00%
No tradesPost-marketLast update at 20:43 GMT
CLLS trade ideas
cellectis alcls : begenning of a new cycle
technicaly , it looks like the last phase of correction has ended, i.e the wave C( impulse with 5 waves)
fundamentaly , cellectis is growing big, has very good product, it's an awesome company
notice :
i'm not a financial adviser
i don't have anything to sell ( signal - education- etc..)
I only post my ideas to force myself to be good and learn from anybody who want to engage in a constructive discussion
please if you see anything wrong in my analysis, let me know
thank you
$CLLS Breakout trade setup inCellectisEntry level $16 = Target price $19.50 = Stop loss $15
Significant break above 200ma.
Average analysts price target $37 | Buy rating
Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following business segments: Therapeutics and Plants. The Therapeutics segment is focused on the development of products in the field of immune-oncology and of novel products outside immuno-oncology to treat other human diseases. The Plants segment focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology through its own efforts or through alliances with other companies in the agricultural market. Its therapeutic products are still in the preclinical stage which is developed for various kinds of tumors. Cellectis was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.
CELLECTIS LONG TERM BUYHi Guys
Following my ideas redarding #cellectis. A promising french biotech company that already celebrates hugh success with "their" ucart19 against leukemia. Check out my thoughts and join the conversatioin.
TA:
- Double bottom which is normally an indicator for a reversal.
- higher high and higher low
- Oversold Stoch RSI (4hr)
- Rising MACD
Fundamentals:
- CASH POSITION OF $ 452M AS OF DECEMBER 31, 2018 COMPARED TO $ 297M AS OF DECEMBER 31, 2017
- CELLECTIS, THROUGH ITS NEW SUBSIDIARY CELLECTIS BIOLOGICS, INC., ENTERED INTO A LEASE AGREEMENT TO BUILD A MANUFACTURING FACILITY IN NORTH CAROLINA, ADVANCING COMMERCIALIZATION CAPABILITIES FOR ITS UCART PORTFOLIO
- UCART123 IN PHASE 1 DOSE ESCALATION CLINICAL TRIAL ONGOING FOR AML
- UCART22 RECEIVED FDA AND IRB APPROVALS FOR PHASE 1 DOSE ESCALATION CLINICAL TRIAL IN B-ALL PATIENTS
- UCART19 ASH ABSTRACT BY PARTNERS SERVIER AND ALLOGENE SHOWED CONTINUED PROGRESS OF FIRST CLINICAL ALLOGENEIC CAR T-CELL PROGRAM FOR ALL ADULT AND PEDIATRIC PATIENTS. MILESTONES PAYMENT CONTRACT WITH PFIZER AND SERVIER UPCOMING
CHECK OUT ALSO THIS AMAZING STORY. WE'RE ABOUT TO CHANCE THE FUTURE BUT ITS A LONG WAY TO GO
google: layla cellectis
